Supernus Pharmaceuticals ((SUPN)) has held its Q2 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Supernus Pharmaceuticals’ recent earnings call conveyed a cautiously optimistic sentiment, highlighting robust growth in core products and a strategic acquisition that promises future expansion. However, the positive outlook was tempered by a decline in operating earnings and rising expenses.
Strong Launch of ONAPGO
ONAPGO, the first and only subcutaneous apomorphine infusion device for Parkinson’s disease, was launched in April. The product exceeded expectations, with more than 750 patient enrollment forms submitted by over 300 prescribers, marking a successful entry into the market.
Acquisition of Sage Therapeutics
Supernus completed the acquisition of Sage Therapeutics on July 31. This strategic move is anticipated to accelerate mid- to long-term revenue growth and enhance cash flow, positioning the company for sustained success.
Growth of Core Products
Core products Qelbree and GOCOVRI demonstrated strong performance. Qelbree prescriptions grew by 23%, with net sales up by 31%. Similarly, GOCOVRI saw a 14% increase in prescriptions and a 16% rise in net sales year-over-year, underscoring the strength of Supernus’ existing portfolio.
Introduction of ZURZUVAE
ZURZUVAE, acquired from Sage Therapeutics, reported net revenues of $23.2 million in Q2 2025, reflecting a significant 68% increase from the previous quarter. This growth highlights the product’s potential contribution to the company’s revenue stream.
Financial Position and Guidance
Supernus ended Q2 with $523 million in cash and marketable securities, reflecting a solid financial position. The company increased its 2025 revenue guidance to a range of $670 million to $700 million, indicating confidence in its growth trajectory.
Decrease in Operating Earnings
Operating earnings on a GAAP basis for Q2 2025 were $12 million, down from $23 million in the same quarter last year. This decline was primarily due to higher sales and marketing expenses associated with the ONAPGO launch.
Flat Total Revenue
Total revenue for Q2 2025 was $165 million, slightly down from $168 million in the same quarter last year. This flat performance reflects the balancing act between new product launches and existing product sales.
Increased Expenses
Combined R&D and SG&A expenses for the first half of 2025 were $233 million, up from $224 million in the same period last year. The increase was driven by the ONAPGO launch and the acquisition of Sage Therapeutics.
Forward-Looking Guidance
Supernus Pharmaceuticals provided updated guidance for full-year 2025, forecasting total revenues between $670 million and $700 million. Non-GAAP operating earnings are expected to range from $105 million to $135 million, reflecting the company’s strategic growth initiatives and robust product pipeline.
In conclusion, Supernus Pharmaceuticals’ earnings call painted a picture of cautious optimism. While the company faces challenges with decreased operating earnings and increased expenses, its strategic acquisitions and strong product launches position it well for future growth. Investors will be keenly watching how these developments unfold in the coming quarters.